Choosing a Safe GLP-1 Compounding Pharmacy: What to Look For

The Safety Question Behind Your Search

You’re researching GLP-1 medication online. You’ve probably found dozens of vendors. Some have clean websites, and some have prices that seem too good to be true. And you’ve likely read headlines about counterfeit products, unregulated pharmacies, or worse. The question that brought you here is the right one: “How do I know if this pharmacy is actually legitimate?”

The reality is straightforward. Not all GLP-1 products sold online come from licensed, regulated pharmacies. Some are sold without a prescription. Some are labeled “for research purposes” or “not for human consumption” while being sold for people to inject. Some contain active ingredients made overseas without appropriate quality controls. The FDA has warned about each of these, and says products like these may contain the wrong ingredients, too much or too little active ingredient, or none at all^[1].

A legitimate compounding pharmacy operates under specific legal requirements and quality standards. These requirements exist to protect you. This guide walks you through what makes a pharmacy legitimate, what credentials actually matter, and the red flags that signal you should look elsewhere.

What a Legitimate Compounding Pharmacy Requires

A Valid Prescription From a Licensed Provider

This is the non-negotiable foundation. If a pharmacy offers to dispense GLP-1 medication without requiring a prescription from a licensed provider, it is not a legitimate pharmacy. Period. The first sign of a safe online pharmacy on the FDA’s list is that it always requires a prescription^[2].

A legitimate prescription comes from a provider who has reviewed your medical history and decided that the medication is appropriate for your situation. That review involves real questions about your health and current medications. It is not something that can happen in minutes.

If you encounter a vendor claiming you can “get a prescription instantly” or “no medical review needed,” move on. These are clear signs the pharmacy is not operating within the law.

An Active State Pharmacy Board License

Every legitimate pharmacy holds a license issued by a state board of pharmacy. The license must be renewed on a schedule the state sets, and the board can discipline, suspend, or revoke a license when a pharmacy breaks the rules.

You can verify a pharmacy’s license yourself. The FDA links to every state’s board of pharmacy license database and says that if an online pharmacy is not listed, you should not use it^[3]. To check:

1. Identify the state where the pharmacy is located.
2. Go to the state board of pharmacy website (the FDA’s BeSafeRx page links to each state’s lookup^[3]).
3. Use the license lookup tool to search for the pharmacy by name or license number.

A legitimate pharmacy will provide its license number and state without hesitation. If a pharmacy is evasive about its license or cannot provide a license number, that is a major red flag.

A Licensed Pharmacist on Staff

Compounding is technical work. Federal law describes 503A compounding in a pharmacy as done by a licensed pharmacist in a state-licensed pharmacy, and 503B compounding as done by or under the direct supervision of a licensed pharmacist^[4]. The FDA also lists “has a licensed pharmacist on staff to answer your questions” as a sign of a safe online pharmacy^[2].

If no licensed pharmacist is available to answer your questions, treat that as a warning sign.

Preparation for Individual Patients, Not Bulk Resale

A traditional 503A compounding pharmacy prepares medication for an identified individual patient based on a valid prescription, and federal law allows it to compound ahead only in limited quantities based on its prescription history^[4]. A 503B outsourcing facility can make batches, but it registers with the FDA, must follow current good manufacturing practice requirements, and federal law bars anyone other than the facility from reselling its products^[4][5].

If a vendor is advertising unlimited inventory of GLP-1 medications to anyone who asks, be cautious. Legitimate compounded GLP-1 availability depends on FDA shortage designations, prescriber orders, and state and federal compounding rules. A legitimate pharmacy dispenses to you only after it receives a valid prescription.

Quality Credentials That Matter

Beyond basic licensing, some credentials and records can tell you more about how a pharmacy operates. Most are not required, and none of them makes a compounded product FDA-approved.

PCAB Accreditation

PCAB stands for Pharmacy Compounding Accreditation Board. It offers voluntary accreditation to compounding pharmacies.

PCAB accreditation is a positive signal, but it is important to understand what it is not: it is not required for a pharmacy to be legitimate, and it is not FDA approval. Many state-licensed pharmacies are not PCAB-accredited. Accreditation is an additional credential, not a substitute for state licensing.

When evaluating a pharmacy, ask: “Are you PCAB-accredited?” If the answer is yes, ask for the details and confirm them with the accrediting body. If the answer is no, the pharmacy may still be fully legitimate; check its license and the other items on this page.

503B Registration (Federal Oversight)

Compounding pharmacies operate under one of two regulatory models:

• 503A pharmacies are overseen mainly by state boards of pharmacy, which have primary responsibility for their day-to-day oversight. The FDA does conduct surveillance and for-cause inspections of them^[5].
• 503B outsourcing facilities register with the FDA, are primarily overseen by the FDA, are inspected on a risk-based schedule, and are subject to current good manufacturing practice (CGMP) requirements^[5][6].

Neither type produces FDA-approved medication. Both can be legitimate. The key difference is the scope of oversight.

If a facility is a registered 503B outsourcing facility, it is subject to FDA inspection and federal manufacturing standards. This is additional oversight, not a replacement for state licensing. Many legitimate pharmacies operate as 503A pharmacies and meet their state requirements.

When evaluating a pharmacy, ask: “Are you a 503A pharmacy or a 503B outsourcing facility?” A pharmacy should be able to answer this clearly. If it says it is a 503B facility, check that it appears on the FDA’s list of registered outsourcing facilities^[6].

Certificate of Analysis (COA)

A Certificate of Analysis is a report of laboratory test results for a specific batch of medication.

Potency testing answers: “Does this batch contain the amount of active ingredient listed on the label?”

Purity and sterility testing answer: “Are contaminants absent?”

Federal law does not require 503A pharmacies to follow CGMP requirements^[5], so testing practices vary from pharmacy to pharmacy. That makes it worth asking. If you are considering a compounded GLP-1 medication, ask whether each batch is tested and whether you can see the COA for the batch you receive. A pharmacy that tests should be able to tell you what it tests for.

You do not need to be a chemist to read a COA. The key things to check:

1. The lot or batch number on the COA matches the lot number on your vial or label.
2. It reports a potency result next to the labeled strength.
3. It names the laboratory that ran the tests and the test date.

If a pharmacy cannot provide a COA or explain how your batch was tested, ask why. If it cannot give a clear answer, look elsewhere.

Clean FDA Inspection History

For 503B outsourcing facilities, the FDA’s registered outsourcing facilities list shows each facility’s last inspection date, whether investigators issued a Form FDA 483 listing objectionable conditions, and any action taken based on that inspection^[6]. The FDA also publishes warning letters in a searchable database on its website^[7].

The FDA’s list does not include state board of pharmacy actions. To find out whether a facility has faced state enforcement, check with the board of pharmacy in the state where it is located^[6]. For a 503A pharmacy, the state board is the main place to look.

If you are evaluating a pharmacy, you can ask: “Have you ever received an FDA warning letter or a state board action?” Then check the answer yourself in the FDA’s warning letter database and on the state board’s website.

A Form 483 or warning letter is not necessarily disqualifying. A Form 483 is not a final agency determination^[6], and some pharmacies take corrective action and continue operating legitimately. However, recent or repeated warning letters are signals of concern.

Red Flags: What to Avoid

Certain characteristics are strong indicators that a source is not a legitimate pharmacy. If you encounter any of these, do not order from that source.

Vendor Bypasses the Prescription Requirement

This is the most important red flag. GLP-1 medications are prescription-only drugs. The FDA lists an online pharmacy that does not require a prescription as a warning sign of an unsafe online pharmacy^[2]. This is not a gray area.

The FDA says illegally marketed semaglutide and tirzepatide sold online^[1]:

• May be counterfeit
• Could contain the wrong ingredients or harmful ingredients
• Could contain too little, too much, or no active ingredient at all

Do not use them, regardless of the price or convenience.

Labeled as “Research Peptide” or “Not for Human Use”

You may encounter sellers offering “research peptides” or products labeled “for research purposes” or “not for human consumption.” The FDA has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, and other GLP-1 ingredients with these labels^[1].

This is deceptive marketing. The FDA says these products have been sold directly to consumers for human use with dosing instructions, even though the label claims otherwise^[1].

The FDA urges consumers not to buy these products because they are of unknown quality and may be harmful to their health^[1].

Do not use these products. The “not for human use” label does not make the product safe for you. It protects the seller.

Ships From Overseas With No US Address

A legitimate US pharmacy gives you a physical address and telephone number in the United States; the FDA lists this as a sign of a safe online pharmacy^[2][3]. If a vendor lists only a foreign address or ships from overseas, that is a red flag.

The FDA’s warning signs for unsafe online pharmacies include^[2]:

• Not being licensed in the United States and by your state board of pharmacy
• Sending medicine that looks different from what you receive at your local pharmacy, or that arrives in packaging that is broken, damaged, in a foreign language, has no expiration date, or is expired

The FDA has also put an import alert in place to help stop GLP-1 active ingredients with potential quality concerns from entering the US, citing foreign-made active ingredients that may be manufactured without appropriate quality controls^[1].

If you cannot identify a US address where the pharmacy is physically located, do not order from it.

Cannot Provide Pharmacy License Number or PCAB Status

A legitimate pharmacy knows its own credentials. It should be able to tell you:

• The state where it is licensed
• Its pharmacy license number
• Whether it is 503A or 503B
• Whether it is PCAB-accredited

If a pharmacy is evasive about these questions, or claims “we don’t give out that information,” that is a red flag. You should be able to verify a pharmacy’s credentials independently. If the pharmacy will not provide the information, why?

Unusually Cheap Pricing

Price alone does not tell you whether a pharmacy is legitimate. However, unusually cheap pricing should raise questions. The FDA lists “deep discounts or prices that seem too good to be true” as a warning sign, both for online pharmacies and for telehealth companies selling GLP-1 drugs^[1][2].

If a pharmacy is offering compounded GLP-1 medication at a price far below what other sources charge, ask why. Possible explanations:

• The source is not a licensed pharmacy and has no quality oversight (cutting costs on testing, verification, etc.)
• The medication is counterfeit or adulterated
• The seller is misrepresenting what you are receiving

Legitimate pharmacies have real costs: licensed pharmacists, lab testing, quality control, regulatory compliance. These costs are reflected in pricing. If a price seems too good to be true, it probably is.

No Licensed Provider Involvement in Prescribing

In a legitimate process, a licensed provider reviews your medical history and makes the prescribing decision. The pharmacy does not decide whether you get medication. The provider does.

If a vendor’s process involves no provider review, or involves a “provider” who reviews your information in seconds without asking questions, that is a red flag. The FDA lists “does not require a screening and prescription” before providing medicine as a telehealth red flag^[1].

What to check before using compounded GLP-1 medication

Transformation Health does not work with, rank, or recommend any compounding pharmacy. These are checks you can run yourself on any pharmacy a provider or program names:

The license. Ask for the pharmacy’s name, state, and license number, then look it up in that state’s board of pharmacy database^[3]. If it is not listed, the FDA says not to use it^[3].

The type. Ask whether it is a 503A pharmacy or a 503B outsourcing facility. If it says 503B, find it on the FDA’s registered outsourcing facilities list and note its last inspection, any Form 483, and any action taken^[6].

The record. Search the FDA’s warning letter database for the pharmacy’s name^[7], and check the state board for any disciplinary actions^[6].

The label. When your medication arrives, check that the pharmacy named on the label is the one you looked up. The FDA has found fraudulent compounded semaglutide and tirzepatide with labels naming pharmacies that do not exist, or licensed pharmacies that did not compound the product^[1]. If the medication comes from a 503B outsourcing facility, federal law requires its label to include the statement “This is a compounded drug” (or a comparable statement), the facility’s name, address, and phone number, the lot or batch number, and the expiration date^[4].

The testing. Ask whether your batch was tested and whether you can see the Certificate of Analysis, and match its lot number to your label.

The active ingredient. Ask what form of semaglutide or tirzepatide the pharmacy uses and where it comes from. The FDA has said some semaglutide sold by compounders may be salt forms, such as semaglutide sodium or semaglutide acetate, which are different active ingredients from those in FDA-approved drugs^[1].

The shipment. Injectable GLP-1 drugs need refrigeration. The FDA recommends not using an injectable GLP-1 drug that arrives warm or without enough refrigeration^[1].

What to Ask Before Getting a Compounded GLP-1 Prescription

If you are considering getting a compounded GLP-1 prescription, here are the questions to ask before you commit:

• About the provider: “What are the provider’s qualifications? Are they a physician, nurse practitioner, or physician assistant? What state(s) are they licensed in?” A legitimate provider will have clear credentials.

• About the pharmacy: “What is the name and location of the pharmacy that will prepare my medication?” Do not accept a vague answer like “we work with a network of pharmacies.” You should know which specific pharmacy is preparing your medication.

• About the license: “What is the pharmacy’s state license number? What state is it licensed in?” Ask for this information. Then verify it independently through the state board of pharmacy website.

• About PCAB accreditation: “Is the pharmacy PCAB-accredited?” A yes is a positive signal, but a no is not disqualifying if the pharmacy is properly licensed and regulated.

• About testing: “Will I be able to see a Certificate of Analysis showing that my batch was tested for potency and sterility?” If the answer is no, ask how the pharmacy checks the quality of what it dispenses.

• About cost: “What is the total cost? Does that include the medication at my likely dose, dose increases, provider visits, labs, shipping, and any membership fee?” Prices vary by program and dose. Understand the full cost before you commit. Ask about cancellation terms.

• About the prescription process: “Will a licensed provider review my medical history before writing a prescription?” The answer should be yes. If the answer is no, or if the provider review happens in minutes with no substantive questions, be cautious.

Transformation Health does not accept payment from providers. How we make money.

FDA Enforcement Context: Why This Matters Now

The FDA keeps a running page of its concerns with unapproved GLP-1 drugs, most recently updated October 1, 2026^[1]. On it, the agency says it:

• Monitors the internet and has issued warning letters to stop the distribution of illegally marketed semaglutide and tirzepatide
• Has warned companies selling GLP-1 drugs falsely labeled “for research purposes” or “not for human consumption”
• Is aware of fraudulent compounded semaglutide and tirzepatide with false information on the label
• Has set up an import alert to help stop GLP-1 active ingredients with potential quality concerns at the border

The same page lists telehealth red flags, including a company claiming a compounded drug is the same as an FDA-approved drug, prices that seem too good to be true, and no screening and prescription by a licensed prescriber before providing medicine^[1].

This reflects the reality: not all GLP-1 products sold online come from legitimate sources. The FDA’s actions highlight the exact risks outlined in this guide.

The enforcement also reinforces an important point: legitimacy is verifiable. A licensed pharmacy can give you a license number you can look up. Illegitimate sources cannot.

The Bottom Line

Choosing a safe compounding pharmacy is not complicated. It requires asking the right questions and verifying the answers independently.

A legitimate pharmacy:

• Fills prescriptions from licensed providers who review your medical history
• Is licensed by a state board of pharmacy (verifiable through the board’s website)
• Has a licensed pharmacist available to answer your questions
• Gives a physical address and phone number in the United States
• Can tell you how your batch was tested
• Provides its credentials without hesitation

If a pharmacy or vendor cannot meet these standards, do not use it.

Whether a GLP-1 medication is appropriate for you is a decision for you and a licensed provider. Where it is prepared is something you can check for yourself.

Important disclosures

This content is for general education and is not medical advice. Talk with a licensed provider about your situation.

Compounded semaglutide and tirzepatide are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed^[1][5]. They are not the same as brand-name products, and they may differ in formulation, purity, and potency.

Regulatory status is subject to change. On December 19, 2024, the FDA reissued its determination that the tirzepatide injection shortage was resolved; it said its enforcement discretion period for 503A pharmacies ended after a March 5, 2025 court decision and for 503B outsourcing facilities on March 19, 2025^[8]. On February 21, 2025, the FDA determined that the semaglutide injection shortage was resolved; it said its 503A period ended after an April 24, 2025 court decision (the original end date was April 22, 2025) and its 503B period ended May 22, 2025^[8]. The FDA says tirzepatide and semaglutide do not currently appear on the 503B bulks list or on its drug shortage list; that page was most recently updated April 1, 2026^[8]. Availability of compounded GLP-1 medications depends on federal and state law and FDA action, and cannot be guaranteed.

Results vary. This page is general information to help you evaluate pharmacies. It does not endorse any pharmacy, provider, or product.

Citations

[1] U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Content current as of 10/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (Accessed 2026-10-16. Supports: illegally marketed semaglutide and tirzepatide online, warning letters, possible counterfeit or wrong-ingredient products; products falsely labeled for research or not for human consumption, sold for human use with dosing instructions; telehealth red flags including sameness claims, prices too good to be true, no screening and prescription; fraudulent compounded labels; salt forms; import alert on GLP-1 APIs; storage on arrival; compounded drugs not reviewed by FDA.)

[2] U.S. Food and Drug Administration. “BeSafeRx: Considering an Online Pharmacy?” Content current as of 09/21/2020. https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/considering-online-pharmacy (Accessed 2026-10-16. Supports: safe signs, including always requiring a prescription, a US physical address and phone number, a licensed pharmacist on staff, and a state board of pharmacy license; warning signs, including not requiring a prescription, not licensed in the US and by your state board, medicine that looks different or arrives damaged, in a foreign language, or without an expiration date, and deep discounts.)

[3] U.S. Food and Drug Administration. “BeSafeRx: Locate a State-Licensed Online Pharmacy.” Content current as of 11/13/2024. https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy (Accessed 2026-10-16. Supports: links to each state’s board of pharmacy license database; if a pharmacy is not listed, do not use it; confirm a prescription requirement, a US address and phone number, and a licensed pharmacist.)

[4] Federal Food, Drug, and Cosmetic Act sections 503A (21 U.S.C. 353a) and 503B (21 U.S.C. 353b). https://www.law.cornell.edu/uscode/text/21/353a and https://www.law.cornell.edu/uscode/text/21/353b (Accessed 2026-10-16. Supports: 503A pharmacy compounding by a licensed pharmacist in a state-licensed pharmacy, for an identified individual patient, with advance compounding only in limited quantities; 503B compounding by or under the direct supervision of a licensed pharmacist; 503B(a)(8) prohibition on wholesaling; 503B(a)(10) label requirements, including “This is a compounded drug,” facility name, address, and phone number, lot or batch number, and expiration date.)

[5] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Content current as of 09/16/2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers (Accessed 2026-10-16. Supports: compounded drugs not FDA-approved and not verified for safety, effectiveness, or quality; state board primary oversight of 503A pharmacies and FDA surveillance and for-cause inspections; FDA primary oversight and risk-based inspection of outsourcing facilities; CGMP applies to outsourcing facilities, not 503A pharmacies; research online pharmacies before buying compounded drugs.)

[6] U.S. Food and Drug Administration. “Registered Outsourcing Facilities.” Content current as of 10/13/2026; table updated as of 9/30/2026. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities (Accessed 2026-10-16. Supports: list of registered 503B facilities with last inspection, Form 483, and action columns; a Form 483 is not a final agency determination; table excludes state board of pharmacy actions, check with the state board.)

[7] U.S. Food and Drug Administration. “Warning Letters.” Content current as of 10/13/2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters (Accessed 2026-10-16. Supports: FDA’s searchable public warning letter database.)

[8] U.S. Food and Drug Administration. “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.” Content current as of 04/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize (Accessed 2026-10-16. Supports: tirzepatide and semaglutide shortage resolution and enforcement discretion dates; not on the 503B bulks list or drug shortage list.)